Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ GuidanceGlobeNewsWire • 08/17/23
Eagle Pharmaceuticals (EGRX) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/08/23
Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023GlobeNewsWire • 08/01/23
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)GlobeNewsWire • 07/24/23
Eagle Pharmaceuticals gets FDA designations that will grant it extra exclusivity for bacterial pneumonia treatmentMarket Watch • 06/14/23
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity ExtensionGlobeNewsWire • 06/14/23
Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual MeetingGlobeNewsWire • 05/11/23
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat EstimatesZacks Investment Research • 05/09/23
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMSGlobeNewsWire • 05/01/23
Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023GlobeNewsWire • 04/27/23
Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)GlobeNewsWire • 04/05/23
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/13/23
Eagle Pharmaceuticals to Present at the Barclays Global Healthcare ConferenceGlobeNewsWire • 03/09/23
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023GlobeNewsWire • 03/03/23